Cyclica Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 54

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $60.6M

Cyclica General Information

Description

Developer of a patented cloud-based predictive analytics software designed to discover safer and more effective medicines. The company's software leverages biophysics and artificial intelligence to improve drug discovery practices by generating a list of putative ligand-protein interactions, enabling health institutions to prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities.

Contact Information

Website
www.cyclicarx.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 207 Queens Quay West
  • Suite 420
  • Toronto, Ontario M5J 1A7
  • Canada
+1 (416)
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Parent Company
Recursion Pharmaceuticals
Vertical(s)
SaaS, Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
Corporate Office
  • 207 Queens Quay West
  • Suite 420
  • Toronto, Ontario M5J 1A7
  • Canada
+1 (416)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cyclica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 25-May-2023 $60.6M Completed Generating Revenue/Not Profitable
11. Grant 15-Nov-2022 Completed Generating Revenue/Not Profitable
10. Grant Completed Generating Revenue/Not Profitable
9. Later Stage VC (Series B) 23-Jun-2020 Completed Generating Revenue/Not Profitable
8. Later Stage VC 01-Jul-2019 Completed Generating Revenue
7. Accelerator/Incubator 01-Oct-2018 Completed Generating Revenue
6. Early Stage VC (Series A2) 26-Jul-2017 Completed Generating Revenue
5. Accelerator/Incubator 29-Sep-2016 Completed Generating Revenue
4. Early Stage VC (Series A1) 22-Sep-2016 $1.84M $3.15M Completed Generating Revenue
3. Seed Round 11-Aug-2015 $1.32M $1.32M Completed Generating Revenue
To view Cyclica’s complete valuation and funding history, request access »

Cyclica Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a patented cloud-based predictive analytics software designed to discover safer and more effective medicine
Drug Discovery
Toronto, Canada
54 As of 2023

Cambridge, MA
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cyclica Competitors (27)

One of Cyclica’s 27 competitors is Exo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exo Therapeutics Venture Capital-Backed Cambridge, MA
OrphAI Therapeutics Venture Capital-Backed New Haven, CT
Relay Therapeutics Formerly VC-backed Cambridge, MA
Owkin Venture Capital-Backed New York, NY
AbCellera Formerly VC-backed Vancouver, Canada
You’re viewing 5 of 27 competitors. Get the full list »

Cyclica Patents

  • 26

    Total Documents Applications and Grants

  • Total Patents Families

  • 12

    Granted

  • 14

    Pending

  • Expiring in next 12 mo

Cyclica Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230138118-A1 Dimethoxyphenylalkylamine activators of serotonin receptors Active 08-Jun-2021
US-11926574-B2 Dimethoxyphenylalkylamine activators of serotonin receptors Active 08-Jun-2021
EP-3906556-A1 Method and system for predicting drug binding using synthetic data Pending 04-Jan-2019
CA-3125513-A1 Method and system for predicting drug binding using synthetic data Pending 04-Jan-2019
EP-3906556-A4 Method and system for predicting drug binding using synthetic data Pending 04-Jan-2019 G16B15/30
To view Cyclica’s complete patent history, request access »

Cyclica Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cyclica Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital
Chiesi Farmaceutici Corporation Minority
China Angels Mentorship Program Accelerator/Incubator Minority
China Canada Angels Alliance Angel Group Minority
Drive Capital Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Cyclica Investments (3)

Cyclica’s most recent deal was a Joint Venture with NineteenGale Therapeutics. The deal was made on 19-Mar-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NineteenGale Therapeutics 19-Mar-2020 Joint Venture Drug Discovery
Rare Diseases Medicine Accelerator 08-Jan-2020 Joint Venture Other Healthcare Services
Entheogenix Biosciences 11-Nov-2019 Joint Venture Drug Discovery
To view Cyclica’s complete investments history, request access »

Ready to get started?

Request a free trial

Cyclica FAQs

  • When was Cyclica founded?

    Cyclica was founded in 2013.

  • Where is Cyclica headquartered?

    Cyclica is headquartered in Toronto, Canada.

  • What is the size of Cyclica?

    Cyclica has 54 total employees.

  • What industry is Cyclica in?

    Cyclica’s primary industry is Drug Discovery.

  • Is Cyclica a private or public company?

    Cyclica is a Private company.

  • What is the current valuation of Cyclica?

    The current valuation of Cyclica is .

  • What is Cyclica’s current revenue?

    The current revenue for Cyclica is .

  • How much funding has Cyclica raised over time?

    Cyclica has raised $22.6M.

  • Who are Cyclica’s investors?

    Bill & Melinda Gates Foundation, Chiesi Farmaceutici, China Angels Mentorship Program, China Canada Angels Alliance, and Drive Capital are 5 of 16 investors who have invested in Cyclica.

  • Who are Cyclica’s competitors?

    Exo Therapeutics, OrphAI Therapeutics, Relay Therapeutics, Owkin, and AbCellera are some of the 27 competitors of Cyclica.

  • When was Cyclica acquired?

    Cyclica was acquired on 25-May-2023.

  • Who acquired Cyclica?

    Cyclica was acquired by Recursion Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »